Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 29;14(7):1738.
doi: 10.3390/cancers14071738.

Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies

Yazeed Samara  1 , Matthew Mei  2
Affiliations
Review

Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies

Yazeed Samara et al. Cancers (Basel). .

Abstract

Standard treatment for relapsed and/or refractory (r/r) Hodgkin lymphoma (HL) consists of salvage therapy, historically consisting of multiagent cytotoxic chemotherapy, followed by autologous stem cell transplantation (autoHCT) in responding patients. With this approach, most patients can proceed to autoHCT, of whom approximately half are cured. However, the introduction of the novel agents brentuximab vedotin (BV) and the checkpoint inhibitors (CPI) nivolumab and pembrolizumab has changed the decision making and peri-transplant decision making, as early incorporation of one or more of these agents can reduce or even eliminate the need for cytotoxic chemotherapy prior to autoHCT. Furthermore, post-autoHCT maintenance therapy with BV has also been shown to decrease relapse in high-risk rel/ref HL patients. In this review, we survey the current data regarding autoHCT in HL with a focus on pre-autoHCT salvage as well as maintenance strategies, and we also talk about the emerging data challenging the long-held dogma of chemosensitivity being a requirement for successful autoHCT.

Keywords: Hodgkin lymphoma; autologous stem cell transplantation; brentuximab vedotin; nivolumab; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Y.S. declares no conflict of interest. M.M. reports Research Support/Funding: TG Therapeutics; Epizyme, Inc.; Bristol Meyers Squibb; BeiGene, Morphosys AG. Honoraria: EUSA; Janssen Pharmaceuticals; Sanofi-Genzyme. Speakers’ Bureau: Morphosys AG.

References

    1. Straus D.J., Długosz-Danecka M., Connors J.M., Alekseev S., Illés Á., Picardi M., Lech-Maranda E., Feldman T., Smolewski P., Savage K.J., et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8:e410–e421. doi: 10.1016/S2352-3026(21)00102-2. - DOI - PubMed
    1. Sasse S., Bröckelmann P.J., Goergen H., Plütschow A., Müller H., Kreissl S., Buerkle C., Borchmann S., Fuchs M., Borchmann P., et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017;35:1999–2007. doi: 10.1200/JCO.2016.70.9410. - DOI - PubMed
    1. Stephens D.M., Li H., Schöder H., Straus D.J., Moskowitz C.H., LeBlanc M., Rimsza L.M., Bartlett N.L., Evens A.M., LaCasce A.S., et al. Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134:1238–1246. doi: 10.1182/blood.2019000719. - DOI - PMC - PubMed
    1. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A.M., Haenel M., Boissevain F., Zschaber R., Müller P., Kirchner H., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002;359:2065–2071. doi: 10.1016/S0140-6736(02)08938-9. - DOI - PubMed
    1. Bröckelmann P.J., Müller H., Casasnovas O., Hutchings M., von Tresckow B., Jürgens M., McCall S.J., Morschhauser F., Fuchs M., Borchmann P., et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann. Oncol. 2017;28:1352–1358. doi: 10.1093/annonc/mdx072. - DOI - PubMed

LinkOut - more resources